నైరూప్య

The role of gut microbiome in cardiometabolic disease.

Ashwini Kumar Ray*, Urvinder S. Kaur, Jyoti Gupta, Alka Yadav, Tannu Bhagchandani, Alok kumar singh, Shalimar, Ravi Tandon*, Rupesh Chaturvedi*

The study of the human microbiota has recently emerged as an area of utmost importance. The human gut microbiome consists of trillions of microorganisms that outnumber human cells and play a vital role in host metabolism. Obesity is a risk factor for cardiometabolic disease (CMD), which includes type 2 diabetes mellitus (T2DM), dyslipidemia, hypertension, cardiovascular disease and non-alcoholic fatty liver disease (NAFLD). Recent studies have shown a connotation between microbiota and CMD. Studies have established that the gut microbiota is one of the crucial factors, which influence the metabolic state of the host and acts as a propeller for the disease. In this review, we focus on the recent findings on the dysbiosis of gut microbiota and CMD pathogenesis and future therapeutic intervention involving gut microbiome manipulation.